Abstract | OBJECTIVES: Severe acute exacerbation (SAE) of chronic hepatitis B (CHB) may progress to liver failure with high potential mortality despite the prompt treatment with nucleos(t)ide analogs. This study aimed to evaluate the efficacy and safety of glycyrrhizin in the treatment of CHB with SAE. METHODS: RESULTS: Patients in group A had significant reductions of serum AST and ALT levels from baseline at days 3, 5, 8, and 15 than those in group B (all P<0.05). The MELD score significantly decreased since week 1 in the group A patients, whereas there were no changes relative to baseline in group B patients at weeks 1 and 2. By week 24, one (3.3%) of group A patients and four (13.3%) of group B patients died (n=3) or received liver transplantation (n=1) (P=0.177). Multivariate analysis identified baseline MELD score (P=0.021) as an independent factor for mortality or receipt of liver transplantation. There were no differences in the rates of grade 3 hypertension, hypokalemia and ascites between two groups. CONCLUSIONS: Early introduction of glycyrrhizin can be safe and helpful for patients with SAE of CHB.
|
Authors | Chao-Hung Hung, Kwong-Ming Kee, Chih-Hung Chen, Po-Lin Tseng, Ming-Chao Tsai, Chien-Hung Chen, Jing-Houng Wang, Kuo-Chin Chang, Yuan-Hung Kuo, Yi-Hao Yen, Tsung-Hui Hu, Sheng-Nan Lu |
Journal | Clinical and translational gastroenterology
(Clin Transl Gastroenterol)
Vol. 8
Issue 6
Pg. e104
(Jun 29 2017)
ISSN: 2155-384X [Print] United States |
PMID | 28662023
(Publication Type: Journal Article)
|